[Study of hepatic function and carbohydrate metabolism during therapy with 6-alpha-methyl-17-alpha-hydroxyprogesterone acetate in adenocarcinoma of the uterine body. I. Influence on the electrophoretic protein pattern, and serum transaminases and alkaline phosphatase].
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood*; D001797:Blood Protein Electrophoresis; D001798:Blood Proteins / Q000096:biosynthesis*; D050260:Carbohydrate Metabolism; D005260:Female; D006801:Humans; D007019:Hypoproteinemia / Q000139:chemically induced; D008099:Liver / Q000187:drug effects*; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D000637:Transaminases / Q000097:blood*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D001798:Blood Proteins; D000637:Transaminases; D000469:Alkaline Phosphatase; D008525:Medroxyprogesterone
Studio della funzionalità epatica e del metabolismo glicidico nel corso della terapia con acetato di 6-alpha-metil-17-alpha-idrossiprogesterone nell'adenocarcinoma del corpo dell'utero. I. Influenza sul quadro elettroforetico proteico, sulle transaminasi e sulla fosfatasi alcalina serica.